Immune checkpoint blockade (ICB) treatment for the clinical
therapy of numerous
malignancies has attracted widespread attention in recent years. Despite being a promising treatment option, developing complementary strategies to enhance the proportion of patients benefiting from ICB
therapy remains a formidable challenge because of the complexity of the tumor microenvironment.
Ibrutinib (IBR), a covalent inhibitor of
Bruton's tyrosine kinase (BTK), has been approved as a clinical
therapy for numerous B-cell
malignancies. IBR also irreversibly inhibits
interleukin-2 inducible T cell kinase (ITK), an essential
enzyme in Th2-polarized T cells that participates in
tumor immunosuppression. Ablation of ITK by IBR can elicit Th1-dominant antitumor immune responses and potentially enhance the efficacy of ICB
therapy in solid
tumors. However, its poor solubility and rapid clearance in vivo restrict T cell targetability and
tumor accumulation by IBR. A
sialic acid derivative-modified nanocomplex (SA-GA-OCT@PC) has been reported to improve the efficacy of IBR-mediated combination
immunotherapy in solid
tumors. In vitro and in vivo experiments showed that SA-GA-OCT@PC effectively accumulated in
tumor-infiltrating T cells mediated by
Siglec-E and induced Th1-dominant antitumor immune responses. SA-GA-OCT@PC-mediated combination
therapy with PD-L1 blockade agents dramatically suppressed
tumor growth and inhibited
tumor relapse in B16F10
melanoma mouse models. Overall, the combination of the SA-modified nanocomplex platform and PD-L1 blockade offers a treatment opportunity for IBR in solid
tumors, providing novel insights for
tumor immunotherapy.